Cloning, protein expression and immunogenicity of HBs-murine IL-18 fusion DNA vaccine.

Simple item page
dc.contributor.authorChannarong, Suneeen_US
dc.contributor.authorMitrevej, Ampolen_US
dc.contributor.authorSinchaipanid, Nuttananen_US
dc.contributor.authorUsuwantim, Kanchanaen_US
dc.contributor.authorKulkeaw, Kasemen_US
dc.contributor.authorChaicumpa, Wanpenen_US
dc.date.accessioned2009-05-27T17:09:06Z
dc.date.available2009-05-27T17:09:06Z
dc.date.issued2007-12-12en_US
dc.descriptionPublished by the Allergy and Immunology Society of Thailand.en_US
dc.description.abstractHepatitis B is a global serious disease caused by hepatitis B virus (HBV). There is no known cure for hepatitis B. The best way to deal with the disease is by preventing with hepatitis B vaccine. However, the current protein-based vaccines made up of recombinant hepatitis B surface antigen (HBsAg) are ineffective in chronic HBV carriers and a significant number of the vaccinees do not mount the protective immune response. Novel DNA-based immunization may overcome the deficits of the protein-based immunization and may provide more effective prophylactic and therapeutic outcomes. In this study, we constructed a recombinant plasmid carrying gene encoding the HBV surface antigen (HBs) linked to DNA segment encoding full-length murine interleukin-18, i.e. pcDNA-HBs-IL-18. Immunogenicity of the DNA construct was carried out in BALB/c mice in comparison with mock, i.e. pcDNA3.1+ and vaccines comprised of pRc/CMV-HBs and pRc/CMV-HBs plus pcDNA-IL-18. All vaccinated mice revealed significant serum anti-HBs IgG response after two intramuscular injections of the vaccines at 28 day interval as compared to the level of mock. Co-administration of pRc/CMV-HBs and pcDNA-IL-18 elicited arbitrarily higher levels of anti-HBs IgG than the levels in mice immunized with pRc/CMV-HBs alone and mice that received pcDNA-HBs-IL-18 although not statistically different. Further experiments are needed to investigate the subisotypes of the IgG antibody, the kinetics of cytokine and the cell-mediated immune response. For this communication, the prototype HBs-IL-18 DNA vaccine was successfully constructed and the gene encoding murine IL-18 was successfully cloned. The latter can be co-injected with the antigen coding DNA or used as a fusion partner to the DNA for priming the immune response. The recombinant HBs and full-length IL-18 proteins have potential for other research purposes. They may be used also as standard proteins in the protein quantification assay.en_US
dc.description.affiliationFaculty of Pharmacy, Mahidol University, Bangkok.en_US
dc.identifier.citationChannarong S, Mitrevej A, Sinchaipanid N, Usuwantim K, Kulkeaw K, Chaicumpa W. Cloning, protein expression and immunogenicity of HBs-murine IL-18 fusion DNA vaccine. Asian Pacific Journal of Allergy and Immunology. 2007 Dec; 25(4): 233-42en_US
dc.identifier.urihttps://imsear.searo.who.int/handle/123456789/36563
dc.language.isoengen_US
dc.subject.meshAnimalsen_US
dc.subject.meshAntibodies, Viral --immunologyen_US
dc.subject.meshHepatitis B --geneticsen_US
dc.subject.meshHepatitis B Surface Antigens --geneticsen_US
dc.subject.meshHepatitis B Vaccines --geneticsen_US
dc.subject.meshHepatitis B virus --geneticsen_US
dc.subject.meshHumansen_US
dc.subject.meshImmunity, Cellularen_US
dc.subject.meshImmunoglobulin G --immunologyen_US
dc.subject.meshInterleukin-18 --geneticsen_US
dc.subject.meshMiceen_US
dc.subject.meshMice, Inbred BALB Cen_US
dc.subject.meshRecombinant Fusion Proteins --geneticsen_US
dc.subject.meshVaccines, DNA --geneticsen_US
dc.titleCloning, protein expression and immunogenicity of HBs-murine IL-18 fusion DNA vaccine.en_US
dc.typeJournal Articleen_US
dc.typeResearch Support, Non-U.S. Gov'ten_US
Files
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.79 KB
Format:
Plain Text
Description:
Download
Collections
Asian Pacific Journal of Allergy and Immunology